Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a gelatin-free live attenuated varicella vaccine developed for the prevention of chickenpox (varicella) in children. Developed or evaluated by the Beijing Center for Disease Control and Prevention, the vaccine contains a live attenuated strain of the varicella-zoster virus (VZV). The primary distinction of this formulation is the absence of gelatin, which is a common stabilizer in vaccines but can cause allergic reactions in some individuals. By removing gelatin, the vaccine provides a safer alternative for children with known gelatin allergies. It is typically administered via subcutaneous injection and has been evaluated in Phase 4 clinical trials to compare its safety and immunogenicity against traditional gelatin-containing varicella vaccines in healthy children aged 1 to 12 years.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gelatin-free live attenuated varicella vaccine.